---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018778"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:27:00.425366+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Appoints Lucy Lu, M.D. to Board of Directors

## Summary
- Lucy Lu, M.D. appointed to Fortress Biotech Board effective December 14, 2022.
- Dr. Lu previously served as Fortress CFO (2012-2017) and CEO of subsidiary Avenue Therapeutics.
- She brings over 20 years of biotech finance and drug development experience including roles at Citigroup.
- Standard-form indemnification agreement entered with Dr. Lu, consistent with other directors' terms.

## SEC filing metadata
- accession: 0001558370-22-018778
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837022018778/0001558370-22-018778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837022018778/fbio-20221214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018778
- JSON: https://secwatch.observer/filing/0001558370-22-018778.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018778.txt

## Key facts
- Executive change
  Lucy Lu, M.D. was elected as Director at Fortress Biotech, Inc..
  - Action: elected
  - Role: Director
  source text: On December 14, 2022, the Board of Directors (the “Board”) of the “Company elected Lucy Lu, M.D. as a new member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837022018778/0001558370-22-018778-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.